Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)


Monday 28 June, 2021

Tissue Regenix Group

Completion of phase 1 of new US facility expansion

RNS Number : 2386D
Tissue Regenix Group PLC
28 June 2021

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")


Completion of phase one of new US facility expansion project


Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces the completion of phase one of its expansion plans, which increases manufacturing capacity at its San Antonio Texas facilities. The San Antonio facilities include the Company's existing facility and a 21,000 sq. ft facility adjacent on which it has a ten-year lease.


The Company announced on 18 March 2021 that it had completed the initial part of its expansion project. Overall, phase one was completed both on time and on budget.


The remaining aspects of phase one consisted of expanding the space for supporting administrative departments, which has taken place in the Company's leased facility adjacent to its existing facility, and building and qualifying two additional clean rooms, which are in the Company's existing facility. The two clean rooms are being used for the processing and packaging of tissue products, bringing the Company's total number of clean rooms to seven. Relocation of the supporting departments to the adjacent facility has also created additional expansion opportunities for production and quality functions in the Company's existing facility.

Daniel Lee, Chief Executive Officer of Tissue Regenix Group plc, said:  "The completion of our phase one expansion plans on time and on budget is excellent news, and provides us additional capacity and flexibility in line with our projected growth in our different target markets. Staging our expansion was a prudent opportunity to meet our demand and capacity needs in an efficient manner."

For more information:


Tissue Regenix Group plc

David Cocke, Chief Financial Officer

Via Walbrook PR



Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price

Tel:  +44(0)20 7710 7600


Walbrook PR Ltd

Alice Woodings / Paul McManus

Tel: +44 (0)20 7933 8780

 [email protected]



About Tissue Regenix ( )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.


In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.




This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t